MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 407880 | Name: OSS-128167
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

OSS-128167, also known as SIRT6-IN-1, is a potent and selective SIRT 6 inhibitor (SIRT6; IC50 = 89 μM). OSS-128167 Restricts Hepatitis B Virus Transcription and Replication Through Targeting Transcription Factor Peroxisome Proliferator-Activated Receptors α. OSS_128167 exerted excellent anti-lymphoma effects via inhibiting PI3K/Akt/mTOR signaling.

Chemical Structure

OSS-128167
OSS-128167
CAS#887686-02-4

Theoretical Analysis

MedKoo Cat#: 407880

Name: OSS-128167

CAS#: 887686-02-4

Chemical Formula: C19H14N2O6

Exact Mass: 366.0852

Molecular Weight: 366.33

Elemental Analysis: C, 62.30; H, 3.85; N, 7.65; O, 26.20

Price and Availability

Size Price Availability Quantity
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 750.00 Ready to ship
200mg USD 1,250.00 Ready to ship
500mg USD 2,650.00 Ready to ship
1g USD 3,750.00 Ready to ship
2g USD 6,150.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
OSS-128167; OSS 128167; OSS128167; SIRT6-IN-1; OSS_128167;
IUPAC/Chemical Name
5-(3-(furan-2-carboxamido)benzamido)-2-hydroxybenzoic acid
InChi Key
HTJWLEGCECXGSQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H14N2O6/c22-15-7-6-13(10-14(15)19(25)26)20-17(23)11-3-1-4-12(9-11)21-18(24)16-5-2-8-27-16/h1-10,22H,(H,20,23)(H,21,24)(H,25,26)
SMILES Code
C1=CC(NC(=O)C2=CC=CO2)=CC(C(=O)NC2=CC=C(O)C(C(O)=O)=C2)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
In cancer and aging-associated pathways, SIRT6 is crucial since it prevents genomic instability, maintains telomere integrity, and regulates metabolic homeostasis and DNA repair. SIRT6 can be considered a double-edged sword in cancer because of its dual role of both tumor suppressor and oncogene. In healthy conditions, SIRT6 either acts as a gatekeeper of DNA repair mechanisms or regulates cell survival and proliferation. Following the DNA damage, SIRT6 triggers the apoptotic process, hence it is down-regulated in several cancers. However, in other cancers, it is up-regulated, corroborating the idea that it can also act as oncogene.
Biological target:
SIRT 6 inhibitor (SIRT6; IC50 = 89 μM)
In vitro activity:
Real-time PCR results revealed that OSS_128167 significantly decreased HBV core DNA level, as confirmed by southern blotting analysis. The level of 3.5-Kb RNA was also modestly decreased after treated with OSS_128167. Similar to its effect on HBV core DNA and 3.5-Kb RNA levels, OSS_128167 treatment also inhibited hepatitis B surface antigen (HBsAg) and hepatitis B envelope antigen (HBeAg) secretions, as well as HBsAg expression in cell lysates. These results above implied that SIRT6 inhibitor OSS_128167 might serve as a potential drug for HBV therapeutics. (reference: Front Pharmacol. 2019; 10: 1270)
In vivo activity:
Antiviral Activity of OSS_128167 in Hepatitis B Virus Transgenic Mouse Model: OSS_128167 showed strong antiviral effect. treatment with OSS_128167 resulted in a marked reduction of intrahepatic HBV DNA, total HBV RNAs and 3.5-Kb RNA level at the end of treatment. By contrast, ETV treatment had no effect on HBV RNA level. Immunohistochemical analysis also showed that OSS_128167 suppressed HBV core protein expression in liver tissues. Taken together, these data showed that OSS_128167 could inhibit HBV transcription and replication in vivo, indicating OSS_128167 might serve as a new therapeutic strategy for HBV treatment. (reference: Front Pharmacol. 2019; 10: 1270) The anti-tumor impact of OSS_128167 on DLBCL cells was further investigated in vivo using a xenograft model of SCID beige mice. Consistent with our in vitro results, obviously decreased tumor growth was noted in the mice treated with OSS_128167 in contrast to the vehicle control group. Additionally, lower expression level of the proliferative marker Ki-67 was observed in OSS_128167 exposed mice. This experiment for the first time performed intraperitoneal inoculation of OSS_128167 onto mice. OSS_128167, a novel targeted inhibitor of Sirt6, exerted excellent anti-lymphoma effects via inhibiting PI3K/Akt/mTOR signaling. In addition, blockade of Sirt6 expression enhanced the sensitivity of DLBCL cells to chemotherapeutic agents. These findings provide mechanistic insights into the oncogenic activity of Sirt6 and highlight the potency of OSS_128167 for novel therapeutic strategies in DLBCL. (reference: J Exp Clin Cancer Res. 2020; 39: 142.)
Solvent mg/mL mM
Solubility
DMSO 30.0 81.90
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 366.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Damonte, P., Sociali, G., Parenti, M.D., et al. SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects. Bioorg. Med. Chem. 25(20), 5849-5858 (2017). 2. Zuo, Y., Huang, L., Enkhjargal, B., et al. Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPARγ/SIRT6/FoxO3a pathway after subarachnoid hemorrhage in rats. J. Neuroinflammation 16(1):47, (2019).
In vitro protocol:
Jiang H, Cheng ST, Ren JH, Ren F, Yu HB, Wang Q, Huang AL, Chen J. SIRT6 Inhibitor, OSS_128167 Restricts Hepatitis B Virus Transcription and Replication Through Targeting Transcription Factor Peroxisome Proliferator-Activated Receptors α. Front Pharmacol. 2019 Oct 25;10:1270. doi: 10.3389/fphar.2019.01270. PMID: 31708789; PMCID: PMC6823301.
In vivo protocol:
Jiang H, Cheng ST, Ren JH, Ren F, Yu HB, Wang Q, Huang AL, Chen J. SIRT6 Inhibitor, OSS_128167 Restricts Hepatitis B Virus Transcription and Replication Through Targeting Transcription Factor Peroxisome Proliferator-Activated Receptors α. Front Pharmacol. 2019 Oct 25;10:1270. doi: 10.3389/fphar.2019.01270. PMID: 31708789; PMCID: PMC6823301.
1: Wu Y, Miao Y, Cao Y, Gong Z. Gastrodin prevents myocardial injury in sleep- deprived mice by suppressing ferroptosis through SIRT6. Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun 19. doi: 10.1007/s00210-024-03230-4. Epub ahead of print. PMID: 38896272. 2: Quan J, Wen X, Su G, Zhong Y, Huang T, Xiong Z, Huang J, Lv Y, Li S, Luo S, Luo C, Cai X, Lai X, Xiang Y, Zheng SG, Shao Y, Lin H, Gao X, Tang J, Lai T. Epithelial SIRT6 governs IL-17A pathogenicity and drives allergic airway inflammation and remodeling. Nat Commun. 2023 Dec 22;14(1):8525. doi: 10.1038/s41467-023-44179-x. PMID: 38135684; PMCID: PMC10746710. 3: Zhang M, Liu W, Liu Y, Zhang Z, Hu Y, Sun D, Li S, Fang J. Astragaloside IV Inhibited Podocyte Pyroptosis in Diabetic Kidney Disease by Regulating SIRT6/HIF-1α Axis. DNA Cell Biol. 2023 Oct;42(10):594-607. doi: 10.1089/dna.2023.0102. Epub 2023 Sep 25. Erratum in: DNA Cell Biol. 2023 Nov;42(11):709. doi: 10.1089/dna.2023.0102.correx. PMID: 37751175. 4: Yu D, Li J, Wang Y, Guo D, Zhu C, Sun B, Zhou Z. Oridonin ameliorates doxorubicin induced-cardiotoxicity via the E2F1/Sirt6/PGC1α pathway in mice. Food Chem Toxicol. 2023 Nov;181:114050. doi: 10.1016/j.fct.2023.114050. Epub 2023 Sep 20. PMID: 37734463. 5: Liu H, Wang S, Gong L, Shen Y, Xu F, Wang Y, Hu L, Zhu L. SIRT6 ameliorates LPS-induced apoptosis and tight junction injury in ARDS through the ERK1/2 pathway and autophagy. Int J Med Sci. 2023 Mar 5;20(5):581-594. doi: 10.7150/ijms.80920. PMID: 37082736; PMCID: PMC10110478. 6: Wang Y, Cai Z, Zhan G, Li X, Li S, Wang X, Li S, Luo A. Caffeic Acid Phenethyl Ester Suppresses Oxidative Stress and Regulates M1/M2 Microglia Polarization via Sirt6/Nrf2 Pathway to Mitigate Cognitive Impairment in Aged Mice following Anesthesia and Surgery. Antioxidants (Basel). 2023 Mar 13;12(3):714. doi: 10.3390/antiox12030714. PMID: 36978961; PMCID: PMC10045012. 7: Nie K, Gao Y, Chen S, Wang Z, Wang H, Tang Y, Su H, Lu F, Dong H, Fang K. Diosgenin attenuates non-alcoholic fatty liver disease in type 2 diabetes through regulating SIRT6-related fatty acid uptake. Phytomedicine. 2023 Mar;111:154661. doi: 10.1016/j.phymed.2023.154661. Epub 2023 Jan 10. PMID: 36682299. 8: Zhou H, Liu S, Zhang N, Fang K, Zong J, An Y, Chang X. Downregulation of Sirt6 by CD38 promotes cell senescence and aging. Aging (Albany NY). 2022 Dec 6;14(23):9730-9757. doi: 10.18632/aging.204425. Epub 2022 Dec 6. PMID: 36490326; PMCID: PMC9792202. 9: Li Z, Zhou L, Du Y, Li H, Feng L, Li X, Han X, Liu H. Polydatin Attenuates Cisplatin-Induced Acute Kidney Injury via SIRT6-Mediated Autophagy Activation. Oxid Med Cell Longev. 2022 Sep 16;2022:9035547. doi: 10.1155/2022/9035547. PMID: 36160707; PMCID: PMC9507782. 10: Wang Z, Wu Q, Wang H, Gao Y, Nie K, Tang Y, Su H, Hu M, Gong J, Fang K, Dong H. Diosgenin protects against podocyte injury in early phase of diabetic nephropathy through regulating SIRT6. Phytomedicine. 2022 Sep;104:154276. doi: 10.1016/j.phymed.2022.154276. Epub 2022 Jun 13. PMID: 35728388. 11: Zou Y, Zhang J, Xu J, Fu L, Xu Y, Wang X, Li Z, Zhu L, Sun H, Zheng H, Guo J. SIRT6 inhibition delays peripheral nerve recovery by suppressing migration, phagocytosis and M2-polarization of macrophages. Cell Biosci. 2021 Dec 14;11(1):210. doi: 10.1186/s13578-021-00725-y. PMID: 34906231; PMCID: PMC8672560. 12: Huang Y, Zhang J, Xu D, Peng Y, Jin Y, Zhang L. SIRT6‑specific inhibitor OSS‑128167 exacerbates diabetic cardiomyopathy by aggravating inflammation and oxidative stress. Mol Med Rep. 2021 May;23(5):367. doi: 10.3892/mmr.2021.12006. Epub 2021 Mar 24. PMID: 33760202; PMCID: PMC7986000. 13: Liu X, Yang Z, Li H, Luo W, Duan W, Zhang J, Zhu Z, Liu M, Li S, Xin X, Wu H, Xian S, Liu M, Liu C, Shen C. Chrysophanol Alleviates Metabolic Syndrome by Activating the SIRT6/AMPK Signaling Pathway in Brown Adipocytes. Oxid Med Cell Longev. 2020 Nov 12;2020:7374086. doi: 10.1155/2020/7374086. PMID: 33274005; PMCID: PMC7683138. 14: Song L, Chen X, Mi L, Liu C, Zhu S, Yang T, Luo X, Zhang Q, Lu H, Liang X. Icariin-induced inhibition of SIRT6/NF-κB triggers redox mediated apoptosis and enhances anti-tumor immunity in triple-negative breast cancer. Cancer Sci. 2020 Nov;111(11):4242-4256. doi: 10.1111/cas.14648. Epub 2020 Oct 7. PMID: 32926492; PMCID: PMC7648025. 15: Yang J, Li Y, Zhang Y, Fang X, Chen N, Zhou X, Wang X. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling. J Exp Clin Cancer Res. 2020 Jul 25;39(1):142. doi: 10.1186/s13046-020-01623-w. PMID: 32711549; PMCID: PMC7382040. 16: Jiang H, Cheng ST, Ren JH, Ren F, Yu HB, Wang Q, Huang AL, Chen J. SIRT6 Inhibitor, OSS_128167 Restricts Hepatitis B Virus Transcription and Replication Through Targeting Transcription Factor Peroxisome Proliferator-Activated Receptors α. Front Pharmacol. 2019 Oct 25;10:1270. doi: 10.3389/fphar.2019.01270. PMID: 31708789; PMCID: PMC6823301. 17: Wang H, Li S, Zhang G, Wu H, Chang X. Potential therapeutic effects of cyanidin-3-O-glucoside on rheumatoid arthritis by relieving inhibition of CD38+ NK cells on Treg cell differentiation. Arthritis Res Ther. 2019 Oct 28;21(1):220. doi: 10.1186/s13075-019-2001-0. PMID: 31661005; PMCID: PMC6819496.

View History

Cyclacillin

Cyclacillin

Kinamycin B

Kinamycin B

3-Acetylbenzophenone

3-Acetylbenzophenone

Tallimustine

Tallimustine